Brokerages Set MoonLake Immunotherapeutics (NASDAQ:MLTX) PT at $81.43

MoonLake Immunotherapeutics (NASDAQ:MLTX) has been given a consensus rating of “Moderate Buy” by the eight brokerages that are covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $81.43.

A number of equities analysts have recently issued reports on the stock. Wedbush reissued an “outperform” rating and set a $73.00 price objective (down previously from $92.00) on shares of MoonLake Immunotherapeutics in a research report on Tuesday, November 5th. Cantor Fitzgerald reiterated an “overweight” rating on shares of MoonLake Immunotherapeutics in a report on Monday, September 23rd. Finally, HC Wainwright restated a “buy” rating and set a $100.00 price objective on shares of MoonLake Immunotherapeutics in a report on Friday, January 10th.

Institutional Investors Weigh In On MoonLake Immunotherapeutics

Several institutional investors have recently bought and sold shares of the stock. US Bancorp DE purchased a new position in MoonLake Immunotherapeutics during the 3rd quarter worth $44,000. Quarry LP lifted its position in shares of MoonLake Immunotherapeutics by 172.7% during the second quarter. Quarry LP now owns 3,000 shares of the company’s stock valued at $132,000 after purchasing an additional 1,900 shares in the last quarter. Barclays PLC boosted its holdings in MoonLake Immunotherapeutics by 1,269.2% during the third quarter. Barclays PLC now owns 5,641 shares of the company’s stock worth $283,000 after purchasing an additional 5,229 shares during the last quarter. Handelsbanken Fonder AB grew its position in MoonLake Immunotherapeutics by 26.2% in the 3rd quarter. Handelsbanken Fonder AB now owns 13,000 shares of the company’s stock worth $655,000 after purchasing an additional 2,700 shares in the last quarter. Finally, AlphaCentric Advisors LLC purchased a new stake in MoonLake Immunotherapeutics in the 3rd quarter valued at about $706,000. Institutional investors own 93.85% of the company’s stock.

MoonLake Immunotherapeutics Stock Performance

Shares of MLTX stock opened at $46.50 on Friday. MoonLake Immunotherapeutics has a fifty-two week low of $37.55 and a fifty-two week high of $64.98. The stock has a 50 day simple moving average of $52.13 and a two-hundred day simple moving average of $49.02. The company has a market cap of $2.97 billion, a P/E ratio of -36.05 and a beta of 1.31.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last released its earnings results on Thursday, November 7th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.12). During the same quarter in the prior year, the business posted ($0.18) EPS. On average, research analysts predict that MoonLake Immunotherapeutics will post -1.75 earnings per share for the current year.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.